ash cll highlights: ibrutinib-venetoclax combination & undetectable mrd in ighv-mutated patients
Published 1 year ago • 534 plays • Length 1:47Download video MP4
Download video MP3
Similar videos
-
1:23
interim analysis of the flair study: efficacy of ibrutinib plus venetoclax in ighv unmutated cll
-
2:09
ash highlights in cll: moving towards fixed-duration treatment, the role of mrd & alpine results
-
2:46
optimizing the combination of ibrutinib plus venetoclax in cll
-
2:00
obinutuzumab, ibrutinib, and venetoclax in high-risk cll: the cll2-give and cll13 trials
-
1:56
ibrutinib plus venetoclax for first-line treatment of cll: 4-year follow-up data
-
2:04
captivate: ibrutinib/venetoclax delivers high rates of umrd in cll
-
3:09
mrd outcomes from glow: venetoclax and ibrutinib in cll
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
5:29
long term follow-up with ibrutinib venetoclax to treat chronic lymphocytic leukemia
-
2:01
the evolution of bcl2 inhibition in cll
-
6:31
an overview of trials investigating asciminib in the treatment of ph cml
-
2:15
highlights in cll at ash and future research
-
2:00
ibrutinib: use in small cll subgroups only?
-
2:41
btk and plcg2 mutations in cll patients taking ibrutinib
-
1:38
ibrutinib and venetoclax upfront for high-risk cll
-
2:18
first-line ibrutinib and venetoclax in cll
-
1:34
the mutational profile in patients with cll treated with acalabrutinib or ibrutinib
-
3:29
avo achieves high rates of undetectable mrd in cll
-
6:34
3-year follow-up of obinutuzumab, ibrutinib and venetoclax for cll
-
2:50
venetoclax and ibrutinib based approaches in cll
-
1:54
glow: assessing ibrutinib plus venetoclax in cll
-
1:53
cll highlights from ash 2023: the flair study